abstract |
The present patent application relates to nanoparticles for the delivery and targeting of a non-tumour-specific antigen in cancer cells, comprising a matrix support based on a biocompatible material, the non-tumour-specific antigen, and an adjuvant, for use in recalling, in cancer patients who have a specific immunity for the non-tumour- specific antigen pre-existing to the tumour pathology, the immune response specific to the non-tumour-specific antigen against the cancer cells. A further object of the application is anti-tumour pharmaceutical formulations comprising nanoparticles and kits comprising the aforementioned anti-tumour pharmaceutical formulations in combination with traditional anti-tumour vaccines. |